Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1930 1
1955 2
1956 1
1959 1
1961 2
1962 1
1963 1
1964 4
1965 2
1966 1
1967 3
1968 5
1969 11
1970 5
1971 7
1972 5
1973 13
1974 16
1975 63
1976 45
1977 43
1978 49
1979 47
1980 61
1981 61
1982 98
1983 93
1984 116
1985 139
1986 144
1987 136
1988 147
1989 151
1990 158
1991 184
1992 178
1993 199
1994 216
1995 212
1996 225
1997 196
1998 181
1999 195
2000 217
2001 221
2002 226
2003 233
2004 261
2005 245
2006 277
2007 268
2008 266
2009 259
2010 299
2011 310
2012 330
2013 309
2014 323
2015 301
2016 284
2017 270
2018 305
2019 318
2020 324
2021 305
2022 288
2023 242
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

9,306 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for indol plus
Your search for tinidol-plus retrieved no results
Bazedoxifene for HRT?
[No authors listed] [No authors listed] Drug Ther Bull. 2017 Apr;55(4):42-44. doi: 10.1136/dtb.2017.4.0466. Drug Ther Bull. 2017. PMID: 28408389 Review.
Duavive (Pfizer) is a modified-release formulation of conjugated oestrogens plus bazedoxifene acetate (a selective oestrogen receptor modulator). ...
Duavive (Pfizer) is a modified-release formulation of conjugated oestrogens plus bazedoxifene acetate (a selective oestrogen receptor …
Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
Qin BD, Jiao XD, Wang Z, Liu K, Wu Y, Ling Y, Chen SQ, Zhong X, Duan XP, Qin WX, Xue L, Guo ZH, Zang YS. Qin BD, et al. Int J Cancer. 2023 Aug 15;153(4):815-825. doi: 10.1002/ijc.34546. Epub 2023 May 8. Int J Cancer. 2023. PMID: 37155342 Clinical Trial.
Thus, our study aimed to evaluate the efficacy and safety of a new regimen of anlotinib plus PD-1 inhibitor to treat refractory solid tumor. APICAL-RST is an investigator-initiated, open-label, single-arm, phase II trial in patients with heavily treated, refractory, metast …
Thus, our study aimed to evaluate the efficacy and safety of a new regimen of anlotinib plus PD-1 inhibitor to treat refractory solid …
CB2 receptor ligands.
Huffman JW. Huffman JW. Mini Rev Med Chem. 2005 Jul;5(7):641-9. doi: 10.2174/1389557054368844. Mini Rev Med Chem. 2005. PMID: 16026310 Review.
Although many cannabinoid receptor ligands show little, or at best modest, selectivity for either receptor, a number of synthetic compounds are known which have significant selectivity for the CB(2) receptor. These include cannabimimetic indoles, such as 1-propyl-2-methyl- …
Although many cannabinoid receptor ligands show little, or at best modest, selectivity for either receptor, a number of synthetic compounds …
Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
Keating GM. Keating GM. Drugs. 2016 Apr;76(5):605-15. doi: 10.1007/s40265-016-0562-7. Drugs. 2016. PMID: 26984388 Review.
In the pivotal coBRIM trial, previously untreated patients with BRAF (V600) mutation-positive unresectable, stage IIIC or stage IV melanoma received cobimetinib 60 mg once daily for the first 21 days of each 28-day cycle plus vemurafenib 960 mg twice daily or vemurafenib a …
In the pivotal coBRIM trial, previously untreated patients with BRAF (V600) mutation-positive unresectable, stage IIIC or stage IV melanoma …
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators. Kolb M, et al. N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. N Engl J Med. 2018. PMID: 30220235 Clinical Trial.
METHODS: We randomly assigned, in a 1:1 ratio, patients with IPF and a Dl(CO) of 35% or less of the predicted value to receive nintedanib at a dose of 150 mg twice daily plus sildenafil at a dose of 20 mg three times daily (nintedanib-plus-sildenafil group) or ninte …
METHODS: We randomly assigned, in a 1:1 ratio, patients with IPF and a Dl(CO) of 35% or less of the predicted value to receive nintedanib at …
GIST: Molecular Profiling Suggests 2nd Therapy.
[No authors listed] [No authors listed] Cancer Discov. 2023 Mar 1;13(3):521-522. doi: 10.1158/2159-8290.CD-NB2023-0008. Cancer Discov. 2023. PMID: 36706070
In an analysis of ctDNA from patients with advanced gastrointestinal stromal tumors, researchers found that, following imatinib therapy, patients with KIT exon 11 plus 17 and/or 18 alterations had superior progression-free survival (PFS) and overall survival (OS) when they …
In an analysis of ctDNA from patients with advanced gastrointestinal stromal tumors, researchers found that, following imatinib therapy, pat …
Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Laubach JP, et al. Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11. Clin Cancer Res. 2015. PMID: 26362997 Review.
Panobinostat was approved based on results from the phase III PANORAMA 1 trial in patients with relapsed or relapsed and refractory multiple myeloma, which showed that panobinostat plus bortezomib and dexamethasone significantly extended progression-free survival (median, …
Panobinostat was approved based on results from the phase III PANORAMA 1 trial in patients with relapsed or relapsed and refractory multiple …
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Metzenmacher M, Rizzo F, Kambartel K, Panse J, Schaufler D, Scheffler M, Azeh I, Hoiczyk M, Turki AT, Atz J, Buchner H, Hoffmann C, C Christoph D. Metzenmacher M, et al. Future Oncol. 2021 Oct;17(30):3965-3976. doi: 10.2217/fon-2021-0424. Epub 2021 Jul 21. Future Oncol. 2021. PMID: 34287064 Free article.
Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known safety profile of docetaxel plus nintedanib. ...Safety findings were generally consistent with the known safety profile of docetaxel …
Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known …
9,306 results